-+ 0.00%
-+ 0.00%
-+ 0.00%

Amgen And 2 More Biotech Stocks To Watch

Simply Wall St·11/15/2026 18:26:34
Listen to the news

US producer prices are rising at a 6.5% annual pace, which keeps funding costs high and makes investors choosier about where to put fresh cash. That backdrop can punish weaker businesses and shine a light on stronger balance sheets. Biotech shares remain risky, but this screen focuses on firms with more reasonable debt and valuation. Below are three of the most interesting biotech stocks pulled from that filter.

The three stocks outlined next are only a sample from the filter. It also surfaced another 80 biotech companies with balance sheets and valuations that may suit investors willing to accept sector risk in search of a potential winner.

If you want to cast a wider net across that broader universe, head straight to the Biotech Stocks screener to identify, compare, and analyze the highest conviction biotech ideas on your own terms.

Amgen (AMGN)

Overview: Amgen is a large biotech group that discovers, develops, manufactures, and sells biologic therapies and biosimilars for serious human diseases.

Operations: Amgen generates about US$38.9b in revenue from Human Therapeutics, with around US$27.7b from the United States and US$10.9b from the rest of the world.

Market Cap: US$251.9b

For the Biotech Stocks theme, Amgen matters because its biologic drugs already generate sizeable cash flows. DKDGI, an investor in the Simply Wall St Community, argues that this cash support gives the group more room to handle risk while still investing in its pipeline.

"Dividend covered about 2x by free cash flow; debt from the Horizon deal is being paid down."

What happens to Amgen’s appeal if one unseen pressure on future cash generation quietly shifts the balance between comfort and concern?

That pressure point is exactly what the full narrative for Amgen unpacks, showing where Amgen’s cash engine could be masking both quiet risks and underappreciated upside.

NasdaqGS:AMGN 1-Year Stock Price Chart
NasdaqGS:AMGN 1-Year Stock Price Chart

Exelixis (EXEL)

Overview: Exelixis is an oncology-focused biotech that discovers, develops, and sells targeted cancer medicines, anchored by CABOMETYX, COMETRIQ, and a growing pipeline.

Operations: Exelixis generates about US$2.5b from cancer medicines, with around US$2.3b coming from the United States and modest contributions from Europe and Japan.

Market Cap: US$16.8b

Exelixis fits the Biotech Stocks theme through its focus on difficult to treat cancers, and the bullish analyst Narrative on Simply Wall St highlights how its existing cabozantinib franchise and emerging zanzalintinib program could reshape the earnings profile if execution lines up.

"The expansion of Exelixis’ GI focused commercial platform and use of more granular utilization data for colorectal and kidney cancer gives zanzalintinib and future assets a ready made sales infrastructure that can support incremental revenue without proportional selling expense growth, which can help operating margins."

The real stress test comes if one assumption about how long cabozantinib can carry that oncology platform quietly tilts the margin story.

If that timing call is wrong, the full narrative for Exelixis shows how Exelixis’ oncology platform could still accelerate or stall as cabozantinib’s role slowly changes.

NasdaqGS:EXEL Earnings & Revenue Growth as at Nov 2026
NasdaqGS:EXEL Earnings & Revenue Growth as at Nov 2026

Johnson & Johnson (JNJ)

Overview: Johnson & Johnson is a diversified healthcare group whose biotech linked Innovative Medicine unit develops prescription therapies across major disease areas worldwide.

Operations: Johnson & Johnson generates about US$64.3b from Innovative Medicine and US$35.0b from MedTech, with US$57.0b coming from the United States.

Market Cap: US$687.9b

For the Biotech Stocks theme, Johnson & Johnson brings scale to high risk drug development through its Innovative Medicine arm. The analyst consensus Narrative on Simply Wall St argues that this pharmaceuticals engine still matters even as MedTech pulls more weight on the top line.

"Johnson & Johnson anticipates accelerated growth in their portfolio and pipeline, particularly in the Innovative Medicine sector, despite the headwind from STELARA's loss of exclusivity."

What happens to Johnson & Johnson’s appeal if one unresolved question about future profitability quietly shifts how durable that biotech cash stream really is?

That hinge point is exactly what the full narrative for Johnson & Johnson lays out, showing where Johnson & Johnson’s pharma engine could be quietly masking both resilience and fresh upside potential.

NYSE:JNJ Earnings & Revenue Growth as at Nov 2026
NYSE:JNJ Earnings & Revenue Growth as at Nov 2026

Seeking Fresh Alternatives Before They Fly

Markets move fast and the sharpest ideas often break out quietly before headlines catch up. Scan fresh momentum pockets while it matters and consider positioning yourself before others react.